The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: A case report

被引：11
作者：
Kim H.S. [1 ]
Kim S.T. [1 ]
Kang S.H. [2 ]
Sung D.J. [3 ]
Kim C.H. [4 ]
Shin S.W. [1 ]
Kim Y.H. [1 ]
Cho W.Y. [1 ]
Park K.H. [1 ]
机构：
[1] Department of Internal Medicine, College of Medicine, Korea University, Seongbuk-Gu, Seoul 136-702
[2] Department of Urology, College of Medicine, Korea University, Seongbuk-GuSeoul 136-702
[3] Department of Radiology, College of Medicine, Korea University, Seongbuk-Gu, Seoul 136-702
[4] Department of Pathology, College of Medicine, Korea University, Seongbuk-Gu, Seoul 136-702
来源：
Journal of Medical Case Reports | / 8卷 / 1期
关键词：
Everolimus; Mammalian target of rapamycin inhibitor; Renal cell carcinoma; Tuberous sclerosis complex;
D O I：
10.1186/1752-1947-8-95
中图分类号：
学科分类号：
摘要：
Introduction. An increased understanding of the genetic pathways involved in renal cell carcinoma has resulted in the development of various drugs that target relevant signaling cascades for the specific treatment of this disease. However, no validated predictive markers have been identified to guide the decision whether patients should receive vascular endothelial growth factor-targeted therapy or mammalian target of rapamycin-targeted therapy. We present what is, to the best of our knowledge, the first case of renal cell carcinoma in a patient with tuberous sclerosis complex who was successfully treated with everolimus. Case presentation. The patient was a 49-year-old Korean woman with tuberous sclerosis complex and recurrent renal cell carcinoma. The patient was treated with the tyrosine kinase inhibitor sunitinib followed by the mammalian target of rapamycin inhibitor everolimus. This treatment resulted in a prolonged response and significant clinical benefit. Notably, everolimus ameliorated the symptoms related not only to renal cell carcinoma but also to tuberous sclerosis complex. Conclusion: This case provides a rationale for the use of everolimus as first-line treatment for this specific patient population in order to target the correct pathway involved in carcinogenesis. © 2014 Kim et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 24 条
  • [1] Crino P.B., Nathanson K.L., Henske E.P., Medical progress: The tuberous sclerosis complex, New England Journal of Medicine, 355, 13, (2006)
  • [2] Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, 45, pp. 228-247, (2009)
  • [3] Linehan W.M., Srinivasan R., Schmidt L.S., The genetic basis of kidney cancer: A metabolic disease, Nat Rev Urol, 7, pp. 277-285, (2010)
  • [4] Escudier B., Bellmunt J., Negrier S., Bajetta E., Melichar B., Bracarda S., Ravaud A., Golding S., Jethwa S., Sneller V., Phase III trial of bevacizumab plus interferon -2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival, J Clin Oncol, 28, pp. 2144-2150, (2010)
  • [5] Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., Negrier S., Chevreau C., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Anderson S., Hofilena G., Shan M., Pena C., Lathia C., Bukowski R.M., Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial, J Clin Oncol, 27, pp. 3312-3318, (2009)
  • [6] Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grunwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A., Study Group R., Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial, Lancet, 372, pp. 449-456, (2008)
  • [7] Motzer R.J., Hutson T.E., Tomczak P., Michaelson D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, New England Journal of Medicine, 356, 2, pp. 115-124, (2007)
  • [8] Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., Zarba J.J., Chen M., McCann L., Pandite L., Roychowdhury D.F., Hawkins R.E., Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial, J Clin Oncol, 28, pp. 1061-1068, (2010)
  • [9] Armstrong A.J., George D.J., Halabi S., Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin, J Clin Oncol, 30, pp. 3402-3407, (2012)
  • [10] Atkins M., Regan M., McDermott D., Mier J., Stanbridge E., Youmans A., Febbo P., Upton M., Lechpammer M., Signoretti S., Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer, Clinical Cancer Research, 11, 10, pp. 3714-3721, (2005)
123